SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001438533-23-000027
Filing Date
2023-05-22
Accepted
2023-05-22 16:30:18
Documents
13
Period of Report
2023-05-17
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tvtx-20230517.htm   iXBRL 8-K 69580
2 EX-99.1 ex991_8-kx20230517eip.htm EX-99.1 213327
  Complete submission text file 0001438533-23-000027.txt   463389

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tvtx-20230517.xsd EX-101.SCH 1899
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tvtx-20230517_lab.xml EX-101.LAB 25154
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tvtx-20230517_pre.xml EX-101.PRE 13044
7 EXTRACTED XBRL INSTANCE DOCUMENT tvtx-20230517_htm.xml XML 11268
Mailing Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130
Business Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130 888-969-7879
Travere Therapeutics, Inc. (Filer) CIK: 0001438533 (see all company filings)

IRS No.: 262383102 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36257 | Film No.: 23944898
SIC: 2834 Pharmaceutical Preparations